Wyeth, Intellipharmaceutics Settle Effexor XR Patent Dispute; Consent Judgment Entered

Wyeth LLC (now part of Pfizer Inc.) and Intellipharmaceutics International Inc. June 20 ended their patent dispute over Intellipharmaceutics’s plan to manufacture a generic copy of Effexor XR (HCl) extended-release capsules (venlafaxine hydrochloride) before three patents covering the drug expire (Wyeth LLC v. Intellipharmaceutics International Inc.).

U.S. District Judge Laura Taylor Swain of the Southern District of New York entered a consent judgment settling the action. The parties stipulated to the dismissal with prejudice of all claims, counterclaims and affirmative defenses in the case, and Intellipharmaceutics stipulated to the validity and enforceability of the patents at issue in ...